OBO_ID (LABEL):	CHEBI_28934 (vitamin D2)

IGNORANCE CATEGORY:	important_consideration

ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
PMC4113768	7/2014	S2617-PMC4113768	['methods: in a double-blind Placebo-controlled randomised trial, 340 Adults (172 from cambridge and 168 from london) at INCREASED RISK of t2d (non-diabetic hyperglycaemia or positive diabetes risk score) were randomised into one of three groups of oral therapy: placebo, 100,000 iu Vitamin D2(Ergocalciferol) or 100,000 iu Vitamin D3(Cholecalciferol) at monthly intervals for four months.']	[('IMPORTANT_CONSIDERATION', 119)]	1	[('CHEBI_26130', 'biological pigment', 27, 'placebo'), ('UBERON_0007023', 'adult organism', 68, 'adults'), ('CHEBI_28934', 'vitamin D2', 281, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 281, 'Vitamin D2'), ('CHEBI_4910', 'etomidate', 292, 'ergocalciferol'), ('CHEBI_33237', 'vitamin D4', 322, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 322, 'Vitamin D3'), ('CHEBI_52550', 'theopalauamide', 333, 'cholecalciferol')]
PMC4600246	10/2015	S4-PMC4600246	['introduction\nVitamin K is a fat-soluble Vitamin, IMPORTANT for the function of numerous proteins within the body, such as the Coagulation factors (ii, vii, Ix, x and protein c and protein s), Osteocalcin (a bone-Forming Protein) and Matrix-Gla Protein (Mgp) (an anticalcification protein), to name a few.1–3vitamin K exists naturally as Vitamin K1(Phylloquinone) and Vitamin K2(Menaquinone, mk-4 through mk-10).2–5vitamin K1Is mainly found in green leafy vegetables as well as olive oil and soyabean oil, whereas Vitamin K2(Menaquinone) is found in small amounts in Chicken, butter, Egg Yolks, cheese and fermented soyabeans (BETTER KNOWN as natto).26–9\nVitamin K1And Vitamin K2Are REQUIRED for the γ-glutamyl carboxylation of all Vitamin K-dependent proteins.2DESPITE the fact that Mammalian bacterial Intestinal flora are able to produce Vitamin K2, the amount produced IS THOUGHT TO be negligible.2the adequate intake (ai) for Vitamin K HAS BEEN PROPOSED to be 90\u2005µg/day for women and 120\u2005µg/day for men.210HOWEVER, it HAS BEEN SPECULATED that the ai for Vitamin K (90–120\u2005µg/day) is not sufficient to induce complete carboxylation of all Vitamin K-dependent proteins.21112\n\nvitamin K deficiency\nthe measurement and treatment of Vitamin K deficiency based on Blood tests is not perfect.']	[('IMPORTANT_CONSIDERATION', 49), ('INCOMPLETE_EVIDENCE', 626), ('IMPORTANT_CONSIDERATION', 682), ('ANOMALY_CURIOUS_FINDING', 760), ('INCOMPLETE_EVIDENCE', 872), ('INCOMPLETE_EVIDENCE', 875), ('INCOMPLETE_EVIDENCE', 940), ('INCOMPLETE_EVIDENCE', 949), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1007), ('INCOMPLETE_EVIDENCE', 1022), ('INCOMPLETE_EVIDENCE', 1031)]	11	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin K'), ('CHEBI_33229', 'vitamin (role)', 40, 'vitamin'), ('GO_0050817', 'coagulation', 126, 'coagulation'), ('PR_000008875', 'islet amyloid polypeptide', 156, 'IX'), ('PR_000011634', 'oxidized low-density lipoprotein receptor 1', 192, 'osteocalcin'), ('PR_000004759', 'Bloom syndrome protein', 211, '-forming protein'), ('GO_0031012', 'extracellular matrix', 233, 'matrix'), ('PR_000010430', 'MAP kinase-interacting serine/threonine-protein kinase 2', 233, 'matrix-Gla protein'), ('PR_000010430', 'MAP kinase-interacting serine/threonine-protein kinase 2', 253, 'MGP'), ('CHEBI_52071', 'dextran', 315, 'K'), ('CHEBI_33229', 'vitamin (role)', 337, 'vitamin'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 337, 'vitamin K1'), ('CHEBI_26124', 'phytosteroid', 348, 'phylloquinone'), ('CHEBI_28934', 'vitamin D2', 367, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 367, 'vitamin K2'), ('CHEBI_18154', 'polysaccharide', 378, 'menaquinone'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 422, 'K1is'), ('CHEBI_28934', 'vitamin D2', 513, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 513, 'vitamin K2'), ('CHEBI_18154', 'polysaccharide', 524, 'menaquinone'), ('NCBITaxon_33208', 'Metazoa', 566, 'chicken'), ('UBERON_0005079', 'eggshell', 583, 'egg yolks'), ('CHEBI_33229', 'vitamin (role)', 654, 'Vitamin'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 654, 'Vitamin K1and'), ('PR_000017209', 'utrophin', 668, 'vitamin K2are'), ('CHEBI_27300', 'vitamin D', 731, 'vitamin K'), ('NCBITaxon_40674', 'Mammalia', 783, 'mammalian'), ('UBERON_0000160', 'intestine', 803, 'intestinal'), ('CHEBI_28934', 'vitamin D2', 840, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 840, 'vitamin K2'), ('CHEBI_27300', 'vitamin D', 930, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 1058, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 1142, 'vitamin K'), ('CHEBI_52071', 'dextran', 1186, 'K'), ('CHEBI_27300', 'vitamin D', 1232, 'vitamin K'), ('UBERON_0000178', 'blood', 1262, 'blood')]
PMC4600246	10/2015	S15-PMC4600246	['Vitamin K and vascular calcifications\nCoronary Artery calcium (cac) HAS BEEN SHOWN to have increasing prevalence as Kidney function declines.3indeed, cac prevalence HAS BEEN reported in 13% of ‘healthy’ patients without Renal disease,2140% of patients with chronic Kidney disease patients not on dialysis,2157% of patients starting dialysis22and 83% of patients on long-term dialysis.23diets lacking Vitamin K can PRECIPITATE the development of Vitamin K deficiency in as little as 7\u2005days.24additionally, subclinical Vitamin K deficiency is not UNCOMMON, especially in patients receiving warfarin.25cross-sectional and cohort data HAVE SHOWN a lower risk of Coronary Heart disease (chd), chd mortality, all-cause mortality and SEVERE Aortic calcifications with higher Vitamin K2(Menaquinone) intake526(box 1).']	[('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 165), ('SUPERFICIAL_RELATIONSHIP', 414), ('INCOMPLETE_EVIDENCE', 545), ('INCOMPLETE_EVIDENCE', 631), ('IMPORTANT_CONSIDERATION', 727)]	6	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin K'), ('UBERON_0001621', 'coronary artery', 38, 'Coronary artery'), ('UBERON_0002113', 'kidney', 116, 'kidney'), ('UBERON_0002113', 'kidney', 220, 'renal'), ('UBERON_0002113', 'kidney', 265, 'kidney'), ('CHEBI_27300', 'vitamin D', 400, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 445, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 517, 'vitamin K'), ('UBERON_0004151', 'cardiac chamber', 658, 'coronary heart'), ('UBERON_0000947', 'aorta', 734, 'aortic'), ('CHEBI_28934', 'vitamin D2', 768, 'vitamin K2'), ('PR_000009450', 'keratin, type II cytoskeletal 1', 776, 'K2'), ('CHEBI_18154', 'polysaccharide', 779, 'menaquinone')]
PMC4600246	10/2015	S16-PMC4600246	['this was NOT SHOWN with vitamin k1intake (Phylloquinone, the major dietary source of Vitamin K.2627thus, dietary vitamin k1intake, without Vitamin K2, MAY not be sufficient to suppress Arterial calcifications and/or reduce RISK for subsequent Cardiovascular events and death.']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 151), ('IMPORTANT_CONSIDERATION', 223)]	3	[('CHEBI_26124', 'phytosteroid', 42, 'phylloquinone'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin K'), ('CHEBI_28934', 'vitamin D2', 139, 'vitamin K2'), ('UBERON_0001637', 'artery', 185, 'arterial'), ('UBERON_0004535', 'cardiovascular system', 243, 'cardiovascular')]
PMC4600246	10/2015	S69-PMC4600246	['the mechanisms responsible include (1) activation of growth-inhibiting proteins requiring Vitamin K2, such as prothrombin,62(2) Arylation pathways,63(3) activation of growth arrest Genes such as gas 6,64and (4) and increased C-Jun and C-Myc mrna Expression in Hepatoma Cells.57\npreventing the Recurrence of hcc is an IMPORTANT STRATEGY, ESPECIALLY CONSIDERING the fact that EVEN after patients undergo curative therapy recurrence rates REMAIN high.65while triple combination therapy with Boceprevir or Telaprevir, pegylated interferon (ifn) and Ribavirin is effective for the treatment of hepatitis c virus (Hcv), INFORMATION on preventing hcc development and/or recurrence as well as all-cause mortality is LACKING.6667moreover, this combination therapy is expensive, REQUIRES injections (ifn) and is OFTEN not well tolerated DUE TO adverse events (ie, fever and pancytopenia).']	[('IMPORTANT_CONSIDERATION', 317), ('FUTURE_WORK', 327), ('IMPORTANT_CONSIDERATION', 337), ('IMPORTANT_CONSIDERATION', 348), ('ANOMALY_CURIOUS_FINDING', 374), ('INCOMPLETE_EVIDENCE', 436), ('INCOMPLETE_EVIDENCE', 614), ('FULL_UNKNOWN', 708), ('INCOMPLETE_EVIDENCE', 708), ('IMPORTANT_CONSIDERATION', 769), ('PROBABLE_UNDERSTANDING', 802), ('PROBLEM_COMPLICATION', 827)]	12	[('CHEBI_28934', 'vitamin D2', 90, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 90, 'vitamin K2'), ('GO_0006915', 'apoptotic process', 128, 'arylation'), ('SO_0000704', 'gene', 181, 'genes'), ('PR_000004968', 'calretinin', 225, 'c-Jun'), ('PR_000000084', 'c-myc protein', 235, 'c-Myc'), ('GO_0010467', 'gene expression', 246, 'expression'), ('CL_0000632', 'hepatic stellate cell', 260, 'hepatoma cells'), ('GO_0000003', 'reproduction', 293, 'recurrence'), ('CHEBI_68621', 'boceprevir', 488, 'boceprevir'), ('CHEBI_68593', 'eurysterol B(1-)', 502, 'telaprevir'), ('CHEBI_63580', 'ribavirin', 545, 'ribavirin'), ('NCBITaxon_10088', 'Mus <genus>', 608, 'HCV')]
PMC4600246	10/2015	S77-PMC4600246	['finally, in the RECENT vitamin k italian (viki) dialysis STUDY, 23.5% of patients were FOUND to be Vitamin K deficient, and this deficiency was FOUND TO BE the strongest PREDICTOR of vertebral fractures (or: 2.94; 95% ci 1.38 to 6.26).72other data HAVE SHOWN that vitamin K2May improve Bone Remodelling in patients with haemodialysis with low Serum Parathyroid hormone levels.73supplementing with at LEAST 200\u2005µg Menaquinone-7 (a form of Vitamin K2) daily MAY help to achieve near maximal protection from vascular calcification, osteoporosis and cancer (measured by maximal gamma carboxylation of Vitamin K dependent proteins).35\n\nconclusion\nVitamin K has a plethora of POTENTIAL IMPLICATIONS, including prevention and treatment of Arterial calcifications, Coronary Heart disease and cancer, improvements in bone strength and reduced risks of fractures as well as improvements in Insulin sensitivity.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 57), ('INCOMPLETE_EVIDENCE', 87), ('ANOMALY_CURIOUS_FINDING', 144), ('SUPERFICIAL_RELATIONSHIP', 170), ('INCOMPLETE_EVIDENCE', 248), ('PROBABLE_UNDERSTANDING', 400), ('INCOMPLETE_EVIDENCE', 456), ('INCOMPLETE_EVIDENCE', 670), ('IMPORTANT_CONSIDERATION', 680)]	10	[('CHEBI_27300', 'vitamin D', 99, 'vitamin K'), ('PR_000009481', 'keratin, type II cytoskeletal 5', 272, 'K2may'), ('GO_0046849', 'bone remodeling', 286, 'bone remodelling'), ('UBERON_0001977', 'blood serum', 343, 'serum'), ('UBERON_0001132', 'parathyroid gland', 349, 'parathyroid'), ('CHEBI_18154', 'polysaccharide', 413, 'menaquinone'), ('CHEBI_28934', 'vitamin D2', 438, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 438, 'vitamin K2'), ('CHEBI_27300', 'vitamin D', 597, 'vitamin K'), ('CHEBI_28384', 'vitamin K', 642, 'Vitamin K'), ('UBERON_0001637', 'artery', 732, 'arterial'), ('UBERON_0004151', 'cardiac chamber', 757, 'coronary heart'), ('PR_000045358', 'insulin family protein', 880, 'insulin')]
PMC5941617	5/2018	S588-PMC5941617	['two studies evaluated the efficacy of administering a bolus dose of Vitamin D2, 150000\xa0iu [225] or 300000\xa0iu [224], every 3\xa0months for 12\xa0months in adolescent females with SEVERE Vitamin D deficiency, with CONFLICTING results.']	[('IMPORTANT_CONSIDERATION', 172), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 206)]	2	[('CHEBI_28934', 'vitamin D2', 68, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 68, 'vitamin D2'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]
